SEC Tracker
Get the app

Verastem VSTM

Verastem (VSTM) filed a 424B5 prospectus supplement, indicating a planned securities offering. This filing provides details on the company's financing activities, which are significant for investors as they signal Verastem's capital-raising efforts to fund its ongoing business operations and growth initiatives. The information in this filing is important for investors to assess the company's financial position and future prospects.

Securities offering

Form
424B5
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Verastem files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  2. DBV Technologies DBVT public float $251M, Jun 30, 2025
  3. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025